Breast Cancer Clinical Trial
Official title:
Combination of DLBS1425 With Anthracyclin-based Regimen as a Neoadjuvant Therapy in Subjects With Stage II or III Breast Cancer
Verified date | May 2013 |
Source | Dexa Medica Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | Indonesia: National Agency of Drug and Food Control |
Study type | Interventional |
This is a 2-arm, randomized, double-blind, placebo-controlled study aiming to determine the
efficacy and safety of DLBS1425 in combination with anthracyclin-based regimen as a
neoadjuvant therapy in subjects with previously untreated stage II or III (operable) breast
cancer.
The anthracyclin-based regimen in the study will be either CAF/iv and CEF/iv only. The
neoadjuvant anthracyclin-based chemotherapy will be given for 3 cycles. The length of each
cycle will be 21-28 days.
Status | Completed |
Enrollment | 40 |
Est. completion date | November 2012 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Confirmed stage II or III (operable) primary breast cancer - Having radiologically evaluable and measurable lesion(s) of the primary tumor - Karnofsky performance status 80 % - Normal cardiac function: LVEF > 50 % - Adequate hematological function: Hb = 10.0 g/dL, WBC = 3,000/mm3, ANC = 1,500 /mm3, platelet count = 100,000/mm3 - Adequate liver function: ALT = 2.5 times upper limit of normal, total bilirubin level = 1.5 times upper limit of normal - Adequate renal function: serum creatinine = 1.5 times upper limit of normal - Able to take oral medication Exclusion Criteria: - Pregnancy or breast feeding subjects - History of previous breast cancer (recurrent breast cancer) - History of other cancer within the past 5 years - Prior systemic treatment for the current breast cancer - Prior preoperative topical treatments for the current breast cancer - Uncontrolled or serious CVD - Known or suspected hypersensitivity to any of the chemotherapeutic agents used in the study - Any other serious disease state or medical condition which judged by investigator could interfere with trial participation or trial evaluation - Concurrent herbal (alternative) medicines or food supplements suspected to have effect on breast cancer disease within 14 days prior to screening - Severe psychological or neurological disorder or dementia that would preclude understanding of the informed consent - Participation in any other clinical studies within 30 days prior to screening |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Indonesia | Surgery-Oncology Division, Department of Surgery, Faculty of Medicine, University of Airlangga / Dr. Soetomo Hospital | Surabaya | East Java |
Lead Sponsor | Collaborator |
---|---|
Dexa Medica Group |
Indonesia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical response as measured by RECIST | Best overall response rate defined as proportion of subjects with either complete or partial response, according to the RECIST criteria at the end of study. | 63 - 84 days | No |
Secondary | Rate of clinical response | Rate of clinical response categorized as complete response, partial response, stable, and progressive disease, which will be evaluated clinically at the end of every cycle | 21 - 84 days | No |
Secondary | Rate of pathological complete response (after surgery) | Pathological complete response based on histological examination will be assessed after surgery. The surgery itself will be performed within 7 - 14 days after the last cycle. | 7 - 14 days after the last cycle | No |
Secondary | Rate of potential breast-conserving procedure | Rate of potential breast-conserving procedure as assessed by mammography, will be evaluated at the end of study. | 63-84 days | No |
Secondary | The change level of relevant biomarkers | Relevant biomarkers related to breast cancer (CEA, CA-15.3, and serum LDH)will be measured at baseline and at the end of every cycle. | 21 - 84 days | No |
Secondary | Haematology | Haematology parameters (Haemoglobin level, Haematocrit, red blood cell count, white blood cell count as well as its differentials, and platelet count) will be evaluated at baseline and the end of every cycle. | 21-84 days | Yes |
Secondary | Liver Function | Liver function parameters (alkaline phosphatase, ALT, AST, bilirubin levels)will be measured at baseline, and the end of every cycle. | 21-84 days | Yes |
Secondary | Renal Function | Renal Function (serum creatinine and Blood urea nitrogen levels) will be measured at baseline and the end of every cycle. | 21-84 days | Yes |
Secondary | Cardiac function | Cardiac function will be assessed by ECHOcardiography at baseline and the end of study. | 63-84 days | Yes |
Secondary | Adverse Events | Adverse events as well as number of subjects experienced the events will be observed and evaluated during the study period (from the first dose of study medication taken (Day 1) till the end of study treatment (Day 63 - Day 84). | 1 - 84 days | Yes |
Secondary | The improvement of quality of life | The improvement of quality of life of the subjects as measured at baseline and at the end of each treatment cycle, using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire (FACIT.org) | 21 - 84 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |